Taxoprexin Pivotal Studies Begin in Melanoma and Pancreatic Cancer

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 11 No 11
Volume 11
Issue 11

KING OF PRUSSIA, Pennsylvania-Protarga, Inc. has received comments from the FDA that allow it to proceed with two separate phase III clinical studies of its new cancer drug Taxoprexin Injection (DHA-pacli-taxel) for the treatment of metastatic melanoma and pancreatic cancer. Taxoprexin is made by linking the fatty acid docosahexaenoic acid (DHA) to paclitaxel, the company said in a news release.

KING OF PRUSSIA, Pennsylvania—Protarga, Inc. has received comments from the FDA that allow it to proceed with two separate phase III clinical studies of its new cancer drug Taxoprexin Injection (DHA-pacli-taxel) for the treatment of metastatic melanoma and pancreatic cancer. Taxoprexin is made by linking the fatty acid docosahexaenoic acid (DHA) to paclitaxel, the company said in a news release.

Articles in this issue
Zoledronic Acid Reduces SREs in Solid Tumors
Study Supports Wider Use of SLN Biopsy in Breast Cancer
Minorities Less Likely Than Whites to Receive Good Pain Care
Polyglutamate-Paclitaxel Controls Recurrent Ovarian Cancer
9cRA Shown to Reverse Premaliagnant Changes in Ex-Smokers
FDA Names New ODAC Chair
Neoadjuvant Weekly Paclitaxel Effective in Advanced Breast Cancer
Docetaxel Plus Gemcitabine Promising in Advanced Pancreatic Cancer
Polysaccharides Unique Targets for Immunotherapy
Genetic Fingerprinting Shows Distinct Sarcoma Subsets
Education on Increased ICP Reduces Nursing ‘Headache’
NCI Begins Trial of Spiral CT vs X-rays as a Screening Test
Good But Short-Lived Responses to Rituximab in LPHD
ODAC Supports Use of Iressa for Third-Line Therapy of NSCLC
Subcutaneous Alemtuzumab Produces High Complete Response Rate in Untreated CLL
Recent Videos
Genetic backgrounds and ancestry may hold clues for better understanding pancreatic cancer, which may subsequently mitigate different disparities.
Factors like genetic mutations and smoking may represent red flags in pancreatic cancer detection, said Jose G. Trevino, II, MD, FACS.
Skin toxicities are common with targeted therapies for GI malignancies but can be remedied by preventative measures and a collaboration with dermatology.
212Pb-DOTAMTATE showed “unexpectedly good” outcomes among those with gastroenteropancreatic neuroendocrine tumors, said Mary Maluccio, MD, MPH, FACS.
Mandating additional immunotherapy infusions may help replenish T cells and enhance tumor penetration for solid tumors, including GI malignancies.
Receiving information regarding tumor-associated antigens or mutational statuses from biopsies may help treatment selection in GI malignancies.
Related Content
Qualified surgeons may offer laparoscopic distal gastrectomy as an alternative to open distal gastrectomy among those with clinical T4a gastric cancer.

Laparoscopic Distal Gastrectomy Appears Feasible in T4a Gastric Cancer

Russ Conroy
December 3rd 2025
Article

Qualified surgeons may offer laparoscopic distal gastrectomy as an alternative to open distal gastrectomy among those with clinical T4a gastric cancer.

Three GI cancer medical oncologists discuss the most significant abstracts in GI cancers from the 2025 ESMO Congress.

How Will Gastrointestinal Cancer Standards of Care Change? An ESMO Recap

Nicholas James Hornstein, MD, PhD;Timothy Brown, MD;Udhayvir S. Grewal, MD
November 3rd 2025
Podcast

Three GI cancer medical oncologists discuss the most significant abstracts in GI cancers from the 2025 ESMO Congress.

Updated results from the phase 1 CK-301-101 trial support the updated label for cosibelimab in this cutaneous squamous cell carcinoma population.

FDA Approves Updated Cosibelimab Label in Cutaneous Squamous Cell Carcinoma

Russ Conroy
December 1st 2025
Article

Updated results from the phase 1 CK-301-101 trial support the updated label for cosibelimab in this cutaneous squamous cell carcinoma population.

A panel of oncology pharmacists discusses the role of lifileucel in metastatic melanoma and other considerations for using cellular therapy in solid tumors.

Optimizing Care for TILs, Cellular Therapy in Melanoma and Solid Tumors

Brooke Adams, PharmD, BCOP;Natalie Brumwell, PharmD, BCOP;Bryant A. Clemons, PharmD, BCOP
October 6th 2025
Podcast

A panel of oncology pharmacists discusses the role of lifileucel in metastatic melanoma and other considerations for using cellular therapy in solid tumors.

How Does NALIRIFOX Fit Into the Metastatic PDAC Treatment Paradigm?

How Does NALIRIFOX Fit Into the Metastatic PDAC Treatment Paradigm?

Ariana Pelosci
November 18th 2025
Article

Results from the NAPOLI 3 trial found NALIRIFOX is a viable option for first-line treatment of metastatic pancreatic adenocarcinoma.

The safety profile of zanidatamab plus chemotherapy with or without tislelizumab was consistent with the known profiles of each individual agent.

Zanidatamab-Based Regimens Exhibit Improved PFS in Gastroesophageal Cancers

Roman Fabbricatore
November 17th 2025
Article

The safety profile of zanidatamab plus chemotherapy with or without tislelizumab was consistent with the known profiles of each individual agent.